Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on March 8, 2018. The registrant is incorporated in California and is designated as an emerging growth company. The filing serves primarily to disclose a press release issued on the same date under Regulation FD (Item 7.01).
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disseminate a press release and does not contain a financial statement or performance summary within the body of the text provided.
Material Changes
No material financial changes or comparative period data are detailed in this filing. The report references a press release (Exhibit 99.1) for the specific nature of the disclosure but does not summarize the content of that release.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words like "may," "will," or "expects" are forward-looking and subject to risks.
- Risk Factors: Specific risks are not listed in this text; investors are directed to the "Risk Factors" section of OncoCyte's Form 10.
- Management Commentary: No specific commentary on operations or outlook is provided in the filing text itself.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Press Release dated March 8, 2018) to understand the specific event triggering this filing.
- Confirm the registrant name is OncoCyte Corporation, as the input metadata referenced a different entity name.
- Review the company's most recent Form 10 for detailed risk factors and financial data, as this 8-K does not contain them.
- Note that the registrant has elected to use the extended transition period for complying with new accounting standards as an emerging growth company.